StockData
Pelthos Therapeutics Inc. logo

Pelthos Therapeutics Inc. (PTHS) stock

PTHSNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30
$6.84−0.31 (-4.34%)

Close on Nov 17, 2026Market cap $26.19MP/E –Yield –

Pelthos Therapeutics cash

Cash and short-term investments held at the end of each period.

Pelthos Therapeutics's cash was $24.19M at Jun 30, 2026. For fiscal 2025 it was $17.97M, up 3403.5% from the year before.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$17.97M+3403.5%
FY2024Dec 31, 2024$513.00K+434.4%
FY2023Dec 31, 2023$96.00K+74.3%
FY2022Dec 31, 2022$55.07K–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$24.19M+40903.4%
Q1 FY2026Mar 31, 2026$31.98M+24309.2%
Q4 FY2025Dec 31, 2025$17.97M+3403.5%
Q3 FY2025Sep 30, 2025$14.20M+1031.7%
Q2 FY2025Jun 30, 2025$59.00K-97.5%
Q1 FY2025Mar 31, 2025$131.00K-96.5%
Q4 FY2024Dec 31, 2024$513.00K+434.4%
Q3 FY2024Sep 30, 2024$1.26M+5407.8%
Q2 FY2024Jun 30, 2024$2.41M+2836.9%
Q1 FY2024Mar 31, 2024$3.77M+7656.4%
Q4 FY2023Dec 31, 2023$96.00K+74.3%
Q3 FY2023Sep 30, 2023$22.79K–
Q2 FY2023Jun 30, 2023$81.89K–
Q1 FY2023Mar 31, 2023$48.61K–
Q4 FY2022Dec 31, 2022$55.07K–

More Pelthos Therapeutics figures

See a number that looks wrong?